BACKGROUND: There are no predictors known that can identify COPD patients who will respond to treatment with ICS. METHOD: We investigated 30 patients (median age 65 (range 44-83, 12 females) with mild to moderately severe COPD. All patients had post bronchodilator FEV1/forced vital capacity ratio of less than 70% and a reversibility of less than 12% and 200 ml from baseline. We wanted to determine if airway responsiveness (AHR) to histamine and mannitol could predict who would respond to a 3-month course of ICS. RESULTS: At baseline, all patients had AHR to histamine, but only 7 (23%) patients to mannitol. After 3 months of treatment with ICS, there was no significant change in spirometry or the quality of life when analysing all individuals together. However, FEV1% predicted improved from 67% (IQR12) to 79% (IQR16) in mannitol positive patients; whereas it was unchanged in the mannitol negative patients. The difference in the mean change of FEV1% predicted between the two groups was 12 (IQR13.5) and this was highly significant (p=0.001). The improvement in quality of life (SGRQ 30 (IQR10.5) to 21 (IQR12; p=0.01) was only significant in the patients positive to mannitol. CONCLUSION: We propose that AHR to mannitol could predict ICS-responsiveness in mild to moderately severe COPD patients.
BACKGROUND: There are no predictors known that can identify COPDpatients who will respond to treatment with ICS. METHOD: We investigated 30 patients (median age 65 (range 44-83, 12 females) with mild to moderately severe COPD. All patients had post bronchodilator FEV1/forced vital capacity ratio of less than 70% and a reversibility of less than 12% and 200 ml from baseline. We wanted to determine if airway responsiveness (AHR) to histamine and mannitol could predict who would respond to a 3-month course of ICS. RESULTS: At baseline, all patients had AHR to histamine, but only 7 (23%) patients to mannitol. After 3 months of treatment with ICS, there was no significant change in spirometry or the quality of life when analysing all individuals together. However, FEV1% predicted improved from 67% (IQR12) to 79% (IQR16) in mannitol positive patients; whereas it was unchanged in the mannitol negative patients. The difference in the mean change of FEV1% predicted between the two groups was 12 (IQR13.5) and this was highly significant (p=0.001). The improvement in quality of life (SGRQ 30 (IQR10.5) to 21 (IQR12; p=0.01) was only significant in the patients positive to mannitol. CONCLUSION: We propose that AHR to mannitol could predict ICS-responsiveness in mild to moderately severe COPDpatients.
Authors: William J Calhoun; Bill T Ameredes; Tonya S King; Nikolina Icitovic; Eugene R Bleecker; Mario Castro; Reuben M Cherniack; Vernon M Chinchilli; Timothy Craig; Loren Denlinger; Emily A DiMango; Linda L Engle; John V Fahy; J Andrew Grant; Elliot Israel; Nizar Jarjour; Shamsah D Kazani; Monica Kraft; Susan J Kunselman; Stephen C Lazarus; Robert F Lemanske; Njira Lugogo; Richard J Martin; Deborah A Meyers; Wendy C Moore; Rodolfo Pascual; Stephen P Peters; Joe Ramsdell; Christine A Sorkness; E Rand Sutherland; Stanley J Szefler; Stephen I Wasserman; Michael J Walter; Michael E Wechsler; Homer A Boushey Journal: JAMA Date: 2012-09-12 Impact factor: 56.272
Authors: Selma B de Nijs; Niki Fens; Rene Lutter; Erica Dijkers; Frans H Krouwels; Barbara S Smids-Dierdorp; Reindert P van Steenwijk; Peter J Sterk Journal: Respir Res Date: 2011-01-18
Authors: Anthony D'Urzo; James F Donohue; Peter Kardos; Marc Miravitlles; David Price Journal: Expert Opin Pharmacother Date: 2015 Impact factor: 3.889
Authors: Jiska B Snoeck-Stroband; Therese S Lapperre; Peter J Sterk; Pieter S Hiemstra; Henk A Thiadens; H Marike Boezen; Nick H T Ten Hacken; Huib A M Kerstjens; Dirkje S Postma; Wim Timens; Jacob K Sont Journal: PLoS One Date: 2015-12-10 Impact factor: 3.240